For an adult patient with in‑transit melanoma stage IIIC, how does intralesional talimogene laherparepvec (T‑VEC) compare to combined checkpoint inhibition with ipilimumab plus nivolumab?

Ipilimumab + Nivolumab is the Preferred First-Line Treatment for Stage IIIC In-Transit Melanoma

For an adult patient with unresectable stage IIIC in-transit melanoma, combination ipilimumab plus nivolumab should be the preferred first-line systemic therapy over talimogene laherparepvec (T-VEC), based on superior progression-free survival, potential for systemic disease control, and stronger guideline support. T-VEC remains a reasonable alternative for patients with isolated cutaneous disease who cannot tolerate systemic therapy or prefer intralesional treatment.

Rationale Based on Guidelines and Evidence

Guideline-Directed Approach

The 2024 NCCN guidelines 1 establish neoadjuvant ipilimumab + nivolumab as a Category 2A preferred regimen for stage III melanoma with satellite/in-transit metastases. The OpACIN-neo trial demonstrated that the "flip-dose" regimen (nivolumab 3 mg/kg + ipilimumab 1 mg/kg for 2 doses) achieved:

• 77% pathologic response rate
• 82% estimated 3-year relapse-free survival
• 92% estimated 3-year overall survival
• Only 20% grade 3-4 immune-related adverse events (significantly lower than standard dosing)

The 2023 ASCO guideline 2 supports combination checkpoint inhibition (nivolumab + ipilimumab) as a reasonable option for advanced melanoma, noting superior PFS compared to single-agent therapy (HR 0.40,95% CI 0.35-0.46).

Real-World Comparative Data

The most relevant head-to-head comparison comes from the Dutch Melanoma Treatment Registry 3, which analyzed 530 patients with unresectable in-transit metastases:

Key Findings:

• Response rates were similar: Anti-PD1 53.1%, T-VEC 52.2%, BRAF/MEK inhibitors 62.7%
• PFS favored systemic therapy: T-VEC median PFS 5.6 months vs. anti-PD1 8.1 months (statistically significant)
• Overall survival: After adjusting for confounders (T-VEC patients had more favorable baseline characteristics), no significant OS difference between T-VEC and anti-PD1
• Melanoma-specific survival: No differences observed between treatments

Critical distinction by disease extent:

• ITM with lymph node involvement: Anti-PD1 showed longer PFS with similar OS compared to T-VEC
• ITM only (no nodes): T-VEC demonstrated longer observed OS, though this likely reflects patient selection bias

Treatment Algorithm for Stage IIIC In-Transit Melanoma

First-Line Decision Framework:

1. Assess Disease Characteristics:

• Presence of lymph node metastases (most stage IIIC has nodal involvement)
• Number and distribution of in-transit lesions
• Systemic disease risk factors (elevated LDH, ECOG performance status)

2. If Lymph Nodes Involved (typical stage IIIC):

• Preferred: Neoadjuvant ipilimumab + nivolumab (flip-dose: nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks × 2 doses) 1
• Followed by surgical resection if feasible
• Then adjuvant systemic therapy based on pathologic response

3. If Isolated In-Transit Disease Without Nodes:

• Option A (Preferred for systemic control): Anti-PD1 monotherapy (pembrolizumab or nivolumab)
• Option B (Reasonable alternative): T-VEC if patient prefers intralesional therapy, has contraindications to systemic therapy, or has easily injectable superficial lesions
• Consider combination T-VEC + anti-PD1 (though not specifically studied in this population)

4. BRAF Status Consideration:

• If BRAF V600 mutant and rapid disease progression: BRAF/MEK inhibitors are an alternative
• However, checkpoint inhibition generally preferred for durability

Practical Considerations

Advantages of Ipilimumab + Nivolumab:

• Addresses both locoregional and potential micrometastatic systemic disease
• Superior PFS in patients with nodal involvement 3
• Pathologic response predicts long-term outcomes 1
• Can be followed by surgery and risk-adapted adjuvant therapy

When T-VEC May Be Appropriate:

• Isolated cutaneous in-transit lesions without nodal disease
• Patient preference for intralesional therapy
• Contraindications to systemic immunotherapy
• Elderly or frail patients who may not tolerate combination checkpoint inhibition
• Accessible lesions amenable to injection

Critical Pitfall to Avoid:

Do not choose T-VEC solely based on "stage IIIC" designation. The presence of lymph node metastases (which defines most stage IIIC disease) fundamentally changes the risk-benefit calculation. T-VEC provides excellent local control but limited systemic protection, making it suboptimal when nodal disease is present 3.

Toxicity Profile:

• Ipilimumab + nivolumab (flip-dose): 20% grade 3-4 immune-related adverse events 1
• T-VEC: Generally well-tolerated with local injection site reactions, flu-like symptoms; rare systemic toxicity 3
• The flip-dose regimen substantially reduces toxicity compared to standard dosing (40% grade 3-4 events) while maintaining efficacy 1

Monitoring and Subsequent Management

After neoadjuvant ipilimumab + nivolumab:

• Assess pathologic response via index lymph node biopsy or surgical specimen
• Major pathologic response (≥90% tumor cell death) predicts 95% 3-year RFS 1
• Tailor adjuvant therapy based on pathologic response

The evidence strongly supports systemic checkpoint inhibition as first-line therapy for stage IIIC in-transit melanoma, particularly when lymph nodes are involved, with T-VEC reserved for select cases of isolated cutaneous disease or when systemic therapy is contraindicated.